Monday 16 November 2026
Export KYNB’s income statement to Excel — free account
Kyntra Bio Inc
KYNBKyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.
- Revenue
- n/m
- EPS
- n/m
- Free cash flow
- n/m
Quarter to June 2026, against a year earlier
3.44
0.15
−4.18%
Follow KYNB
Alert me
Kyntra Bio Inc (KYNB) news
Headlines
- Kyntra Bio to Report Third Quarter 2026 Financial Results GlobeNewswire
- Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors GlobeNewswire
- Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
- Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript The Motley Fool transcript
- Kyntra Bio Inc (KYNB) (Q2 2026) Earnings Call Highlights: Advancing FG-3246 and Roxadustat with ... transcript
- Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates
- Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
- Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates
- Kyntra Bio to Report Second Quarter 2026 Financial Results
- Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?
- Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates
- NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimates
- Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
- Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances ... GuruFocus.com
- Kyntra Bio (KYNB) Q1 2026 Earnings Transcript The Motley Fool transcript
- Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates Zacks
- Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
- Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates Zacks
- Kyntra Bio to Report First Quarter 2026 Financial Results GlobeNewswire
- Replays from RedChip's Biotech Investor Conference Now Available
- Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know Zacks
- RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech Innovation ACCESS Newswire
- Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference GlobeNewswire
- Kyntra Bio Inc (KYNB) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline with ... GuruFocus.com
- Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript The Motley Fool transcript
- Kyntra Bio: Q4 Earnings Snapshot Associated Press Finance
- Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update GlobeNewswire
- Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
- Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates Zacks